On April 26, Kunqi Pharmaceutical (832952) recently released its 2020 annual report. During the reporting period, the company achieved an operating income of 1252739.19 yuan, a year-on-year decrease of 52.17%; The net profit attributable to the shareholders of the listed company was -2964164.17 yuan, which was lower than that of the same period of last year.
During the reporting period, the net cash flow from operating activities was -363862.61 yuan, and the net assets belonging to the shareholders of the listed company was 1789113.23 yuan by the end of 2020.
During the reporting period, the operating cost was 1792354.42 yuan, a decrease of 1235300 yuan or 40.80% compared with the previous period. The main reason was the decrease of operating revenue and corresponding operating cost. In addition, affected by the epidemic, the market development progress was delayed and the corresponding market expenditure was less.
The administrative expenses were 1599401.14 yuan, a year-on-year decrease of 17.78%. The main reason is that there are still some administrative expenses that need to be paid annually.
According to the data of digbei.com, Kunqi Pharmaceutical Co., Ltd. is a manufacturer of traditional Chinese medicine decoction pieces. Relying on the cultivation and processing experience of traditional Chinese medicine and professional talents of traditional Chinese medicine, Kunqi Pharmaceutical Co., Ltd. provides “boutique” and “high-end” famous traditional Chinese medicine decoction pieces with Yunnan characteristics represented by very fine Sanqi powder for hospitals, pharmaceutical companies and retail institutions.